May 19, 2025 | Biosimilars, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
Nov 21, 2024 | Bariatric surgery, GLP-1s, MedBen Rx, Wegovy, Weight loss, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are seeing...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
